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Abstract
Background  and  objectives:  Postoperative  bleeding  has  a  great  clinical  importance  and  can  con-
tribute to  increased  mortality  and  morbidity  in  patients  undergoing  coronary  artery  bypass  graft
surgery. In  this  prospective,  randomized,  double-blind  study,  we  evaluated  the  effect  of  pro-
phylactic  administration  of  ﬁbrinogen  concentrate  on  post-coronary  artery  bypass  graft  surgery
bleeding.
Methods:  A  total  of  60  patients  undergoing  coronary  artery  bypass  surgery  were  randomly
divided into  two  groups.  Patients  in  the  ﬁbrinogen  group  received  1  g  of  ﬁbrinogen  concentrate
30 min  prior  to  the  operation,  while  patients  in  the  control  group  received  placebo.  Post-
operative bleeding  volumes,  prothrombin  time,  partial  thromboplastin  time,  INR,  hemoglobin
and transfused  blood  products  in  both  groups  were  recorded.  A  strict  red  blood  cell  transfusion
protocol was  used  in  all  patients.
Results:  There  were  no  signiﬁcant  differences  between  intra-operative  packed  red  blood  cells
infusion in  the  studied  groups  (1.0  ±  1.4  in  ﬁbrinogen  group,  and  1.3  ±  1.1  in  control  group).
Less postoperative  bleeding  was  observed  in  the  ﬁbrinogen  group  (477  ±  143  versus  703  ±  179,
p =  0.0001).  Fifteen  patients  in  the  ﬁbrinogen  group  and  21  in  the  control  group  required  post-
op packed  red  blood  cells  infusion  (p  =  0.094).  No  thrombotic  event  was  observed  through  72  h
after surgery.
Conclusion:  Prophylactic  ﬁbrinogen  reduces  post-operative  bleeding  in  patients  undergoing
coronary  artery  bypass  graft.
© 2013  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
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Estudo  randômico  e  duplo-cego  de  proﬁlaxia  com  ﬁbrinogênio  para  reduzir  o
sangramento  em  cirurgia  cardíaca
Resumo
Justiﬁcativa  e  objetivo:  A  hemorragia  no  período  pós-operatório  é  de  grande  importância
clínica e  pode  contribuir  para  o  aumento  da  morbidade  e  mortalidade  em  pacientes  submetidos
à cirurgia  de  revascularizac¸ão  coronária.  Nesse  estudo  prospectivo,  randômico  e  duplo-cego,
avaliamos  o  efeito  da  administrac¸ão  proﬁlática  de  concentrado  de  ﬁbrinogênio  sobre  o  sangra-
mento após  cirurgia  de  revascularizac¸ão  coronária.
Métodos:  No  total,  60  pacientes  submetidos  à  cirurgia  de  revascularizac¸ão  coronária  foram
randomicamente  divididos  em  dois  grupos.  Os  pacientes  do  grupo  ﬁbrinogênio  receberam  1  g
de concentrado  de  ﬁbrinogênio  30  minutos  antes  da  operac¸ão,  enquanto  os  doentes  do  grupo
controle receberam  placebo.  Os  volumes  de  sangramento  no  pós-operatório,  tempo  de  pro-
trombina,  tempo  de  tromboplastina  parcial,  INR,  hemoglobina  e  hemoderivados  transfundidos
em ambos  os  grupos  foram  registrados.  Um  protocolo  de  conduta  rigoroso  para  transfusão  de
hemácias  foi  usado  em  todos  os  pacientes.
Resultados:  Não  houve  diferenc¸as  signiﬁcantes  entre  as  infusões  de  concentrados  de  hemácias
nos grupos  estudados  (1,0  ±  1,4  no  grupo  ﬁbrinogênio  e  1,3  ±  1,1  no  grupo  controle).  O  grupo
ﬁbrinogênio  apresentou  menos  sangramento  no  pós-operatório  (477  ±  143  versus  703  ±  179,
p =  0,0001).  Quinze  pacientes  do  grupo  ﬁbrinogênio  e  21  do  grupo  controle  precisaram  de  infusão
de concentrado  de  hemácias  no  pós-operatório  (p  =  0,094).  Evento  trombótico  não  foi  observado
durante 72  h  após  a  cirurgia.
Conclusão:  Proﬁlaxia  com  ﬁbrinogênio  reduz  o  sangramento  no  período  pós-operatório  de
pacientes submetidos  à  revascularizac¸ão  coronária.
© 2013  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
Introduction
Optimal  prevention  and  management  of  intra-  and  post-
operative  bleeding  has  a  great  clinical  importance  in  various
types  of  surgeries,  including  coronary  artery  bypass  graft
surgery  (CABG).  Such  management  can  efﬁciently  decrease
the  amount  of  blood  products  transfusion  and  as  a  result,
may  lead  to  less  transfusion  related  complications.
Two  to  6  percent  of  CABG  surgery  patients  would  be  re-
explored  due  to  intraorpost-operative  hemorrhage,  which
can  lead  to  high  morbidity  and  mortality  rates.  Further-
more,  complications  such  as  sternal  wound  infections  are
more  frequent  along  with  post-operative  transfusion.1--2
Consequently,  the  importance  of  any  approach  or  inter-
vention  to  decrease  intra-  or  post-operative  hemorrhage
is  obvious.2 Coagulopathy  is  one  possible  reason  of  exces-
sive  bleeding  during  and  following  surgery.  Multiple  factors
including  platelet  dysfunction,  ﬁbrinolysis  and  coagulation
factor  deﬁciencies  may  affect  post-operative  bleeding  fol-
lowing  cardiac  surgery.3
During  CABG  surgery,  low  ﬁbrinogen  plasma  concen-
tration  may  directly  be  associated  with  blood  loss.4 This
association  is  likely  since  ﬁbrinogen  is  essential  in  the  cross-
linking  of  platelets  during  primary  hemostasis  and  plays  a
central  role  in  the  coagulation  cascade,5 and  it  had  been
shown  that  following  hemorrhage,  ﬁbrinogen  concentration
decreases  more  than  other  coagulationfactors.6--9
The  purpose  of  present  study  was  to  investigate  the
effect  of  pre-operative  infusion  of  ﬁbrinogen  concentrate  on
post-operative  bleeding  volume  in  CABG  surgery  patients.
The  percentage  and  amount  of  transfused  blood  products
were  considered  as  secondary  outcome  parameters.
Methods
Following  the  approval  of  the  study  protocol  by  the  Insti-
tutional  Ethics  Committee,  this  trial  was  registered  by  the
Iranian  Registry  of  Clinical  Trial.  All  participants  provided  a
written  form  of  consent  after  they  were  fully  informed  of
nature  and  design  of  the  study.
Sixty  patients,  scheduled  for  ﬁrst  time  elective  CABG,
were  enrolled  in  this  double-blinded  randomized  placebo-
controlled  clinical  trial.  The  patients  with  the  following
criteria  were  not  considered  eligible  to  take  part  in  this
study:  previously  diagnosed  hematologic  or  liver  diseases,
uncontrolled  or  insulin  dependent  diabetes,  pregnancy,
unstable  angina,  serum  creatinine  more  than  130  mol/L,
left  ventricular  ejection  fraction  less  than  35%,  serum  ﬁb-
rinogen  levels  more  than  3.5  g/L.  The  patients  also  needed
to  be  mentally  capable  of  giving  a  written  informed  consent.
Using  a computer  generated  randomization  list,  patients
were  assigned  to  ﬁbrinogen  and  control  groups.  All  the
required  study  drugs  were  prepared  by  an  anesthetist  who
was  not  involved  in  the  surveillance  of  the  patients.  Fur-
thermore,  all  the  ﬂuid  plastic  containers  were  covered  by
textile,  so  content  of  plastic  containers  was  invisible.
Anticoagulant  therapy  with  aspirin,  warfarin  and  clopi-
dogrel  was  discontinued  48  h prior  to  surgery.  On  arrival  to
the  operating  room,  all  the  patients  received  oxygen  via  a
facemask  at  a  rate  of  4  L/min,  and  an  18-gauge  intravenous
catheter  was  placed  in  a  peripheral  vein  to  allow  for  hydra-
tion  of  the  patients  using  lactated  ringer’s  solution  (7  mL/kg)
and  administration  of  medications.  Standard  monitoring
which  consisted  of  invasive  and  non-invasive  arterial  blood
pressure,  heart  rate,  electrocardiogram,  pulse  oximetry,
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and  capnometery  was  initiated  and  continued  throughout
anesthesia.
Anesthesia  was  induced  by  1  mg  of  IV  midazolam,  8  g/kg
of  IV  fentanyl  and  3  mg/kg  of  IV  sodium  thiopental,  and
0.1  mg/kg  of  IV  pancuronium  bromide.  Prior  to  the  start
of  surgery  a  percutaneous  central  venous  line  was  placed.
Isoﬂurane  was  used  for  maintaining  general  anesthesia.
Before  beginning  of  cardiopulmonary  bypass,  a  baseline  acti-
vated  clotting  time  (ACT)  was  measured  and  an  IV  bolus
dose  of  heparin  (400  U/kg)  was  administered  to  all  patients.
Next  heparin  dosing  was  targeted  to  maintain  ACT  values
more  than  480  seconds.  Myocardial  protection  techniques
were  identical  in  both  groups,  and  priming  of  the  blood  car-
dioplegialine  was  performed  on  CPB  with  autologous  blood.
Identical  ﬂuid  therapy  was  used  in  both  groups.
In  the  ﬁbrinogen  group  the  patients  received  1  gram  of
ﬁbrinogen  dissolved  in  50  mL  of  normal  saline  over  a  15  min
period  30  min  before  induction  of  anesthesia.  In  the  control
group  the  patients  were  administered  the  same  volume  of
normal  saline  during  the  same  period  of  time  as  a  placebo.
All  the  drugs  were  prepared  and  administered  by  an  anes-
thetist  who  was  not  anyhow  involved  in  the  study.
Hemoglobin  concentration,  platelet  count,  partial
thromboplastin  time  (PTT),  prothrombin  time  (PT)  and
plasma  ﬁbrinogen  concentrations  were  measured  before
induction  of  general  anesthesia  and  were  repeated  again
24  h  following  surgery.  Plasma  concentrations  of  ﬁbrinogen
were  adjusted  to  a  standard  hematocrit  of  40%  accord-
ing  to  the  formula:  corrected  concentration  =  measured
concentration  ×  (standard  hematocrit/measured  hemat-
ocrit).  Hematocrit  levels  were  measured  every  30  min  until
termination  of  bypass.  Red  blood  cells  were  transfused  if
the  intraoperative  hematocrit  was  less  than  20%.  In  the
intensive  care  unit,  hematocrit  values  less  than  25%  were
considered  as  transfusion  trigger.  Plasma  was  administered
in  patients  with  ongoing  bleeding  and  abnormal  PT  or
PTT.  Platelets  were  transfused  with  ongoing  bleeding  and
platelets  count  less  than  7  ×  109 per  liter.
Post-operative  bleeding  was  described  as  the  overall
chest  tube  drainage  during  the  ﬁrst  12  post-operative  hours
and  was  recorded  by  a  trained  intensive  care  nurse.  The
amount  of  transfused  packed  red  blood  cells,  fresh  frozen
plasma,  and  platelets  during  the  ﬁrst  24  h  post-surgery  were
also  documented.  For  a  period  of  72  h  following  surgery  clin-
ical  signs  and  symptoms  of  thrombotic  adverse  effects  were
followed  and  recorded.  If  any  of  these  events  occurred,  the
patient  was  considered  a  candidate  for  further  evaluation
such  as  Doppler  ultrasound.
Statistics
It  was  determined  that  a  sample  size  of  18  patients  in  each
group  would  be  sufﬁcient  to  detect  a  minimum  of  200  mL
bleeding  differences  in  12  h  following  surgery  with  a  stan-
dard  deviation  of  150  mL,  power  of  90%  and  a  signiﬁcant
level  of  0.01.
Statistical  analysis  of  the  data  was  performed  using  SPSS
for  windows  version  17  (SPSS,  Chicago,  IL).  The  distribution
of  data  was  checked  by  Kolmogorov--Simonov  test,  which
consisted  of  a  normal  distribution.  Group  comparisons  were
performed  with  two-sample  t-tests  for  continuous  data.  Sex
was  compared  by  2 test.  Statistical  signiﬁcance  was  deﬁned
as  a  p-value  <  0.05.
Results
A  total  of  60  patients  (70%  male,  30%  female)  were  enrolled
in  this  study.  There  was  no  protocol  violation  and  all  of
the  participants  were  included  in  the  analysis.  Basic  char-
acteristics  of  the  participants  such  as  age,  weight,  height,
aortic  clamp  time  and  number  of  anastomoses  were  similar
between  both  groups  (Table  1).  Baseline  and  post-operative
laboratory  variables  including  PTT,  PT,  hemoglobin  concen-
tration  and  platelet  count  in  both  ﬁbrinogen  and  control
groups  were  similar  (Table  2).
Post-operatively,  a  lower  blood  loss  was  observed  in  the
ﬁbrinogen  group  (477  ±  143)  in  comparison  with  the  con-
trol  group  (703  ±  179)  (p  <  0.0001)  (Fig.  1).  Fifteen  (50%)
patients  in  the  ﬁbrinogen  group  and  21  (70%)  patients  in
the  control  group  received  packed  red  blood  cells  post-
operatively,  and  there  were  no  signiﬁcant  differences  in
groups  (p  =  0.094).  Yet,  total  amount  of  packed  red  blood
cells  infusion  in  groups  did  not  differ  signiﬁcantly  (p  =  0.096).
Table  1  Basic  characteristics  of  the  patients  and  baseline  coagulation  values.
Fibrinogen  group  Control  group
Female/male  10/20  8/22
Age (years)  59  ±  9  58  ±  9
Weight (kg)  73  ±  14  71  ±  11
Height (cm)  164  ±  8.9  164.6  ±  6.9
Base line  ﬁbrinogen  (g  L−1)  2.7  ±  0.3  2.7  ±  0.3
Aortic clamp  time  (min)  52.2  ±  12.1  56.8  ±  8.0
Anastomoses  (numbers)  2.8  ±  0.4  2.6  ±  0.4
Post-op packed  red  blood  cell  transfusion  (n)  1.5  ±  1.8  2.0  ±  1.5
Heparin (units  administered)  34,000  ±  9500  36,000  ±  11,000
Baseline hemoglobin  (g  L−1)  13.8  ±  1.5  13.6  ±  1.6
PTT (s)  29.9  ±  6.4  28.8  ±  6.6
PT (s) 12.4  ±  0.9  12.4  ±  0.7
Platelets (L−1)  2,570,000  ±  99,223  255,733  ±  56,774
a Data were presented mean ± SD.
b There is no signiﬁcant difference between groups.
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Table  2  Coagulation  at  postoperative  day  1.
Post-operative  value  Fibrinogen  group  Control  group
Hemoglobin  (g  dL−1) 9.7  ±  1.39 8  ±  1.2
PTT (s)  40.5  ±  25.2  44.7  ±  18.1
PT (s)  15.6  ±  8.5  14.6  ±  2.1
Platelets (L−1)  1,670,000  ±  55,000  1,680,000  ±  54,000
Fibrinogen (g  dL−1)  2.9  ±  0.4  2.9  ±  0.4
a Data were presented as mean ± SD.
b There is no signiﬁcant difference in groups.
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Figure  1  Post-operative  bleeding  (the  overall  chest  tube
drainage  during  the  ﬁrst  12  post-operative  hours)  in  the  ﬁb-
rinogen  group  (1)  compared  to  the  control  group  (2).
There  were  no  signiﬁcantly  differences  in  the  number  of
packed  red  blood  cells  infusion  in  groups  (1.5  ±  1.8  in  the
ﬁbrinogen  group,  and  2.0  ±  1.5  in  the  control  group).  Four
patients  in  the  ﬁbrinogen  group  received  fresh  frozen  plasma
to  in  comparison  to  2  in  the  control  group  (ns).  Only  one  of
patients  in  the  ﬁbrinogen  group  received  a  platelet  transfu-
sion.
In  neither  of  groups  any  clinically  apparent  thrombotic
events  were  found.
Discussion
This  study  showed  that  the  immediate  preoperative  adminis-
tration  of  ﬁbrinogen  concentrates  to  CABG  surgery  patients
can  decrease  post-operative  hemorrhage.
Surgical  bleeding  is  a  major  concern  in  cardiac  surgery.10
Preventing  blood  product  transfusion  and  decreasing  hem-
orrhage  dependent  re-exploration  rates  improve  patients’
outcomes  and  could  lower  the  overall  burden  on  health  care
costs.11
Relatively  low  ﬁbrinogen  concentrations  may  play  an
important  role  in  bleeding  following  cardiac  surgery.12,13
Low  preoperative  ﬁbrinogen  level  has  been  found  to  be
an  independent  predictor  of  post-operative  bleeding  and
transfusion,13 low  ﬁbrinogen  levels  during  and  after  CABG
surgery  were  found  to  be  associated  with  bleeding14,15
and  ﬁbrinogen  administration  after  cardiopulmonary  bypass
reduced  the  bleeding  signiﬁcantly.16 And  last  but  not  least,
in  the  so  far  only  small  prospective  randomized  study,  Karls-
son  et  al.  showed  in  20  patients  that  the  preoperative
administration  of  2  g  of  ﬁbrinogen  decreased  postoperative
blood  loss  and  minimized  the  decrease  of  the  hemoglobin
concentration  postoperatively.13 Our  study  conﬁrms  these
results  and  expands  the  knowledge  in  a  larger  group  of  60
patients  in  that  already  the  administration  of  1  g  of  ﬁbrino-
gen  is  capable  of  reducing  postoperative  bleeding  in  patients
undergoing  ﬁrst  time  CABG  surgery.
Karlsson  et  al.  also  looked  at  thrombotic  complications
and  concluded  that  the  administration  of  2  g of  ﬁbrinogen
was  safe  in  this  regard.12 We  conﬁrm  this  conclusion  in  a
larger  group  of  patients  although  we  only  assessed  clinical
thrombotic  events.  We  thus  concluded  that  prophylac-
tic  ﬁbrinogen  infusion  signiﬁcantly  reduces  post-operative
bleeding  without  clinical  adverse  events.  Yet,  the  investiga-
tion  of  Karlson  et  al.  was  a  pilot  study  and  only  10  patients
participated  in  it.  So,  the  power  of  study  is  not  sufﬁcient  to
make  a  strong  conclusion.  In  our  study,  prophylactic  adminis-
tration  of  the  lower  amount  of  ﬁbrinogen  (1  g)  could  reduce
the  post-operative  blood  loss  by  32%;  however,  the  decrease
in  a  blood  transfusion  was  not  signiﬁcant  but  there  was  a
trend.
In  our  study,  the  packed  red  blood  cells  infusion  was
not  different  statistically  in  groups;  however,  based  on  cal-
culated  p value  (p  =  0.096),  it  is  possible  that  the  power
of  the  study  was  not  sufﬁcient  to  show  such  a  differ-
ence.  As  the  present  sample  size  was  estimated  considering
post-operative  hemorrhage  as  a  primary  outcome,  a  higher
powered  study  is  necessary  to  assess  the  effect  of  ﬁbrinogen
concentrate  administration  on  post-CABG  packed  red  blood
cells  infusion.
There  are  limitations  of  this  study  such  as  the  lack  of  any
form  of  thromboelastometric  monitoring  (TEG  or  ROTEM)
perioperatively  and  the  ﬁxed  dose  (1  g)  of  ﬁbrinogen.  Future
studies  with  individualized  and  more  precise  coagulation
monitoring  are  needed  to  deﬁne  the  optimal  dose  of  ﬁb-
rinogen.  The  rationale  for  choosing  the  present  dosage  was
based  on  a  previous  study  conducted  by  Karlsson  et  al.13
and  due  to  the  fact  that  the  plasma  ﬁbrinogen  level  was
not  evaluated  frequently  in  our  study  aiming  at  decreasing
the  postoperative  blood  loss  along  with  minimal  thrombotic
adverse  effects.
In conclusion,  administration  of  1  g  of  intravenous  ﬁb-
rinogen  concentrate  before  induction  of  general  anesthesia
in  CABG  surgery  can  reduce  post-operative  bleeding.
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